Integra LifeSciences IART Neurosurgery — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's neurosurgery — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's neurosurgery — total revenues?
- Integra LifeSciences (IART) reported neurosurgery — total revenues of $198.2M in Q1 2026.
- How has Integra LifeSciences's neurosurgery — total revenues changed year-over-year?
- Integra LifeSciences's neurosurgery — total revenues increased by 3.8% year-over-year, from $190.91M to $198.2M.
- What is the long-term trend for Integra LifeSciences's neurosurgery — total revenues?
- Over 4 years (2021 to 2025), Integra LifeSciences's neurosurgery — total revenues has grown at a 0.8% compound annual growth rate (CAGR), from $802.96M to $827.67M.
- What does neurosurgery — total revenues mean?
- This metric represents the total net revenue generated from the sale of products and services within the neurosurgery business segment. It captures the financial performance of specialized medical devices and surgical instruments designed for neurosurgical applications, reflecting the segment's market demand and commercial success. Monitoring this figure allows investors to assess the growth trajectory and competitive positioning of the company's neurosurgical portfolio relative to broader market trends.